Chicago-based CRISPR technology company Syntax Bio says it has developed tech which automates the slow, manual process of ...

Overview: The demand for programming skills in 2026 centres around versatility, performance, and scalability as companies ramp up AI, cloud, and web services.La ...

Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly ...

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupix ...

Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for ...

Texas Children's Hospital in Austin performs fetal blood transfusion to save the life of baby exposed to childhood illness.

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo ...

A new study led by scientists at the Perception Dynamics Institute and the University of California San Diego demonstrates ...

The daily burden for those living with type 1 diabetes is constant, and Breakthrough T1D remains focused on accelerating the path to cures for the disease,” said Nicholas Mamrak, Ph.D., scientist at ...

As the global population ages, 2025 has delivered a remarkable wave of new research aimed at supporting healthier brains in ...

Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function.1,2 -- Affecting up to 100,000 people in the U.S. and up to 5.6 ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of new research in Science Advances detailing the company’s CRISPR-based ...